The prognosis of patients with advanced endometrial cancer is poor with limited therapeutic options. Nevertheless, the integration of molecular features in the clinico-pathological classification of endometrial cancer has significantly refined prognostic risk groups, representing a major breakthrough not only in the management of the disease but also in treatment perspectives. New therapeutic compounds such as target therapies, immunotherapy, and hormonal therapies have emerged for this clinical setting. Furthermore, molecular-driven clinical trials may improve significantly the efficacy of new treatments selecting those patients who are highly likely to respond. This review aims at describing the state of the art of advanced stage III-IVa endometrial cancer management, providing also the most interesting clinical perspectives.
- uterine cancer
- endometrial neoplasms
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors CN: conceptualization, methodology, data curation, resources, project administration, writing – original draft, writing – review and editing. DL: conceptualization, writing – original draft, visualization, supervision, project administration, writing – review and editing. FT: writing – original draft, visualization, supervision, writing – review and editing. EG: data curation, investigation, methodology, visualization, supervision. GS: writing – original draft, visualization, supervision, writing – review and editing.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests GS has served on advisory boards for TESARO Bio Italy S.r.l, Johnson &Johnson, Clovis Oncology Italy S.r.l. He received support for travel or accommodation from MSD Italy S.r.l and Clovis, Oncology Italy S.r.l, and institutional research funding from MSD Italy S.r.l; DL has served on advisory boards for Clovis Oncology, AstraZeneca, Genmab/Seattle Genetics, MSD, ImmunoGen, PharmaMar, Roche, and Tesaro/GSK, received support for travel or accommodation from AstraZeneca, GSK and Roche and institutional research funding from Merck, GSK, Clovis, Pharmamar.
Provenance and peer review Commissioned; internally peer reviewed.